ClinicalTrials.gg
CompletedNCT03267498Updated Jan 12, 2026Results posted

Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)

A Phase 2 interventional study of Nivolumab and Cisplatin in Nasopharyngeal Carcinoma, sponsored by Sue Yom. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by Sue Yom · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies testing nivolumab in Nasopharyngeal Carcinoma — 2 open to participants now, 5 under way, none of them phase 3. Nivolumab · Nasopharyngeal Carcinoma.

Enrollment
8th of 10
40 · median 54
Started
2018
with 1 other
Phase 2
9 of 10
2 open now
Registered
4th of 10
by date
Lead sponsor
1 of 10
Sue Yom

Among the 10 studies testing nivolumab in Nasopharyngeal Carcinoma, this one is the 8th largest by enrollment, is one of 2 that started in 2018, is one of 9 in phase 2, and was the 4th registered.

Nasopharyngeal Carcinoma

683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.

Browse Nasopharyngeal Carcinoma studies →

Open to participants now

2 of the 10 studies testing nivolumab in Nasopharyngeal Carcinoma are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 186 Nasopharyngeal Carcinoma studies recruiting now, 42 (23%) set no upper age limit and 135 (73%) stop at 75 or younger; 9 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing nivolumab in Nasopharyngeal Carcinoma, or all of them as a file.
02

Study summary

This phase II trial studies how well nivolumab and chemoradiotherapy works in treating patients with stage II-IVB nasopharyngeal cancer. Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells. Chemoradiotherapy is the combination of chemotherapy and radiation therapy and may prevent the cancer from spreading when combined with nivolumab. Giving nivolumab and chemoradiotherapy may work better in treating patients with stage II-IVB nasopharyngeal cancer.

Read the detailed description

PRIMARY OBJECTIVES:

I. To establish the feasibility of treatment completion of a combined chemoradiation-nivolumab regimen followed by adjuvant nivolumab.

SECONDARY OBJECTIVES:

I. To determine the overall response rate at 1 year from end of treatment, as determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.

II. To determine the locoregional control rate at 1 year post-treatment.

III. To determine the distant metastasis rate at 1 year post-treatment.

IV. To determine the rate of Epstein-Barr virus (EBV) deoxyribonucleic acid (DNA) clearance at end of chemoradiation and at 1 year from end of treatment.

V. To determine the acute and late toxicity rates according to Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 5, including immune-related adverse events (AEs).

VI. To assess patients' quality of life from baseline through 1 year from end of treatment.

EXPLORATORY OBJECTIVES:

I. To determine the overall survival rate at 5-year post-treatment.

II. To determine whether programmed death-ligand 1 (PD-L1) -positive immunohistochemistry and novel quantitative assays correlate to clinical outcome.

III. To determine if the density of infiltrating Cluster of differentiation 3 (CD3)+ T cells/μm2 correlates to clinical outcome.

IV. To monitor immune changes by flow cytometry in the circulating T cell response to EBV antigens.

V. To compare the change in the circulating T-cell repertoire by TCR sequencing and single-cell T-cell profiling.

VI. To quantify treatment-induced changes over time in the circulating T cell immune response to EBV using T-cell receptor (TCR) sequencing and enzyme-linked immunospot (ELISPOT) assays.

OUTLINE:

Patients receive nivolumab intravenously (IV) over 60 minutes on day 1 of courses 1-5 and 7-12. Treatment repeats every 14 days for 11 courses in the absence of disease progression or unacceptable toxicity. Beginning at course 2, patients undergo radiation therapy once daily (QD) 5 days per week and receive cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 7 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 1, 3, 6, 9, and 12 months for up to 1 year and then survival follow-up information may be collected via telephone calls, clinic follow-up visits, or medical records review for up to an additional 4 years. Survival and disease status will be collected until participant death, withdrawal, or if the participant is lost to follow-up.

03

Conditions studied

  • Nasopharyngeal Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females ≥18 years of age.
  2. or cytologically confirmed nasopharyngeal carcinoma, stage II-IV by American Joint Committee on Cancer (AJCC) 7th edition, endemic-type (defined as World Health Organization (WHO) type 2a and 2b nonkeratinizing or undifferentiated subtypes, excluding WHO type I keratinizing subtype) performed on a that occurred within 90 days of registration.
  3. Positron emission tomography-computed tomography (PET-CT) (preferred) or a CT of chest, abdomen, and pelvis within 60 days of registration showing radiographic stage II to IVB nasopharyngeal cancer.
  4. No distant as verified by one of the study investigators.
  5. Documentation that the patient is a candidate for chemoradiation of their nasopharyngeal cancer by one of the study investigators.
  6. Ability to tolerate radiation therapy (e.g. lie flat and hold position for treatment).
  7. as defined by v1.1.
  8. (ECOG) performance status of 0 to 1.
  9. Lack of to systemic immunotherapy (see list of exclusions below).
  10. Resolution of all acute toxic effects of any prior chemotherapy, radiotherapy or surgical procedures to Version 5.0 grade 1.
  11. Adequate hepatic, hematologic, and renal indices permitting administration of cisplatin and nivolumab (within 14 days of registration):

    Hepatic Function:

    (AST) and alanine aminotransferase (ALT) ≤ 3 × (ULN); Total ≤ 1.5 × ULN (except subjects with Gilbert Syndrome, who can have total bilirubin \< 3.0 mg/dL)

    Adequate bone marrow function:

    White blood cells (WBC) ≥ 2000/μL Neutrophils ≥ 1500/μL ≥ 100 x103/μL > 9.0 g/dL

    Adequate renal function:

    Serum creatinine ≤ 1.5 × upper limit of normal (ULN) OR

    (CrCl) > 40 mL/min (or > 50 mL/min for Singapore sites only) (if using the Cockcroft-Gault formula below):

    Female CrCl = (140 - age in years) x weight in kg x 0.85 72 x serum creatinine in mg/dL Male CrCl = (140 - age in years) x weight in kg x 1.00 72 x serum creatinine in mg/dL

  12. Women of must have a negative serum pregnancy test within 24 hours prior to the first dose of study treatment and agree to use appropriate highly effective methods of , during the study and for 5 months following completion of study treatment; A "Woman of childbearing potential" is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not . Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 62 must have a documented serum follicle stimulating hormone (FSH) level less than 40 milli-international units per milliliter (mIU/mL).

    Female Subjects:

    Women of child bearing potential are expected to use one of the highly effective methods of contraception listed in the protocol.

    Male Subjects:

    Male subjects must inform their female partners who are women of child bearing potential of the contraceptive requirements and are expected to adhere to using contraception with their partner. Female partners of male subjects, who are women of child bearing potential, are expected to use one of the highly effective methods of contraception listed in the protocol. In addition, male subjects are expected to use a condom as noted in the protocol.

  13. Men with a female partner of childbearing potential must agree to use highly effective methods of contraception or any contraceptive method with a failure rate of less than 1% per year during the study and for 7 months following completion of study treatment.
  14. Ability to sign .

Exclusion criteria

Exclusion Criteria:

  1. Active second , i.e. patient known to have potentially fatal hematologic malignancy or another solid primary tumor present for which he/she may be (but not necessarily) currently receiving treatment. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are allowed to enroll in this trial. For example, patients with early-stage skin cancers, prostate cancer under surveillance with non-rising prostate-specific antigen (PSA), or meningioma or thyroid papillary cancers which are under surveillance are eligible. For determinations of a specific clinical condition, please consult with the Principal Investigator.
  2. Active, untreated central nervous system (CNS) ;
  3. Prior treatment with any other anti-programmed cell death protein-1 (), or PD Ligand-1 (PD-L1) or PD Ligand-2 (PD-L2), anti-cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways, or cancer vaccine;
  4. Prior systemic cytotoxic therapy, antineoplastic biologic therapy, or major surgery within 28 days of first dose of study medication;
  5. Severe reaction to treatment during prior administration of a monoclonal antibody (mAb) or history of allergy to any study drug component;
  6. Has received a live-virus vaccination within 30 days of planned treatment start;
  7. Condition requiring systemic treatment with either (> 10 mg daily prednisone equivalents) or other medications within 14 days of study drug administration; Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active disease.
  8. Any evidence of current interstitial lung disease (ILD) or pneumonitis or a prior history of ILD or pneumonitis requiring oral or IV glucocorticoids;
  9. Active, known, or suspected autoimmune disease or any autoimmune condition that has required systemic treatment in the past 2 years (replacement therapies for hormone deficiencies are allowed); Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger.
  10. Clinically active diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction, or abdominal carcinomatosis (known risks factors for bowel perforation);
  11. Signs or symptoms of infection within 2 weeks prior to first day of study treatment.
  12. Patients with active tuberculosis (clinical evaluation in line with local practice), or a known history of active tuberculosis that in the opinion of the treating investigator has a high risk of reactivation.
  13. Received therapeutic oral or IV antibiotics within 2 weeks prior to first day of study treatment: Patients receiving prophylactic antibiotics (eg, to prevent a urinary tract infection or exacerbation) are eligible.
  14. Known positive test for (HIV);
  15. Known active or virus (HBV or HCV): Patients with past or resolved HBV infection (defined by a negative hepatitis B surface antigen (HBsAg) test and a positive anti-hepatitis B core antigen (HBc) (anti-HBc)antibody test) are eligible. HBV DNA must be obtained in these patients prior to first day of study treatment. Patients who have been recently discovered to have HBV with positive HBsAg test and positive anti-HBc antibody test but who have been started on antiretroviral treatment with nondetectable HBV DNA are eligible. HBV DNA must be obtained in these patients prior to first day of study treatment
  16. Patients with known active hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection: Patients positive for HCV antibody are eligible only if Polymerase chain reaction (PCR) test is negative for HCV RNA.
  17. Prior radiation therapy of any type within 7 days of first dose of study medication;
  18. Prior radiation therapy to head and neck region that would overlap with intended radiation treatment for nasopharyngeal carcinoma;
  19. Medical to radiation treatment (e.g. active systemic sclerosis, other uncontrolled autoimmune condition)
  20. Treatment with prohibited medications (including concurrent anticancer therapy including chemotherapy, radiation, hormonal treatment [except corticosteroids and megestrol acetate] ≤ 14 days prior to treatment.
  21. Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study;
  22. Active, uncontrolled psychiatric disorders or substance (drug/alcohol) abuse that interfere with patient's safety, ability to provide , or ability to comply with the protocol.
  23. Persons who are incarcerated or otherwise under compulsory detention by an authority are not eligible.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Nivolumab + chemoradiation

    Patients receive nivolumab IV over 60 minutes on day 1 of courses 1-5 and 7-12. Treatment repeats every 14 days for 11 courses in the absence of disease progression or unacceptable toxicity. Beginning at course 2, patients undergo radiation therapy QD 5 days per week and receive cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 7 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.

    Drug: Nivolumab · Drug: Cisplatin · Radiation: Radiation Therapy

Interventions

  • Dosage 240mg of Nivolumab will be given intravenously over 60 minutes, every 14 days.

    Also known as: Opdivo

  • Dosage 40 mg/m2 of cisplatin will be given intravenously over 30-60 minutes, every 7 days.

  • RadiationRadiation Therapy

    2.12 Gy/fraction x 33 fractions of radiation therapy will be given, daily Monday - Friday

06

What researchers measure

Primary outcomes

  1. Rate of Completion of All Adjuvant Immunotherapy

    The rate of completion of all adjuvant therapy by patients treated at the maximum tolerated dose (MTD) schedule will be determined and compared to a historical control rate of 52%, the rate of completion of a standard adjuvant cisplatin-based platform to determine feasibility of study treatment

    Time frame: Up to 1 year

Secondary outcomes

  1. Overall Response Rate (ORR)

    The ORR is based on the best overall response (BOR) recorded from the first day of treatment until time of assessment. The percentages of patients with a best overall response rate of complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) will be determined as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.

    Time frame: Up to 1 year after completion of treatment

  2. Number of Treatment-related Adverse Events (AEs)

    Adverse events will be classified using the National Cancer Institute Common Toxicity Criteria (NCI-CTCAE) version 5.0 by the investigator assessment and reported by frequency of Adverse Events (AEs) attributed as definitely, probably, or possibly related to the study interventions.

    Time frame: Up to 1 year after completion of treatment

  3. Mean Loco-regional Control (LRC) Rate

    Duration of LRC will be calculated as 1+ the number of days from the first day of treatment to time of documented locoregional clinical or radiographic relapse, progression or death due to any cause. For patients who continue treatment post-progression, the date of clinical or radiographic relapse or progression will be used for analysis. The Kaplan-Meier analysis will be used to calculate the mean LRC rate with full range.

    Time frame: Up to 1 year after completion of treatment

  4. Mean Distant Metastasis (DM) Rate

    Time to DM will be calculated as 1+ the number of days from the first day of treatment to documented clinical or radiographic progression at a distant metastatic site, or death due to any cause. Pathologic confirmation is not required to document the date of distant progression. For patients who continue treatment post-progression, the date of clinical or radiographic progression will be used for analysis. The Kaplan-Meier analysis will be used to calculate the mean DM rate with full range.

    Time frame: Up to 1 year after completion of treatment

  5. Mean Change in Scores on the Functional Assessment of Cancer Therapy - Nasopharyngeal Cancer (FACT-NP)

    The FACT-NP is a self-report instrument that measures multidimensional quality of life (QOL) in patients with Nasopharyngeal cancer-specific scale. The FACT-NP consists of 43 questions that address physical, social, emotional, and functional well-being, with additional specific questions relevant to persons with nasopharyngeal cancers. Each item has a score range of 0 (Not at all) to 4 (Very much). For the 37 general health and head and neck cancer sections, the raw score range is 0-148, with the higher scores indicating better QOL reported by the participant. The 6 remaining questions for the nasopharyngeal cancers also fall on the same range of 0 to 4, with a raw total score range of 0-24, but on this subscale, lower scores indicate a higher QOL.

    Time frame: Up to 1 year after completion of treatment

  6. Percentage of Participants With Acute Toxicities

    Acute toxicity rates will be reported and classified according to CTCAE version 5 and include immune-related AEs

    Time frame: Up to 1 year after completion of treatment

  7. Percentage of Participants With Late Toxicities

    Late toxicity rates will be reported and classified according to CTCAE version 5 and include immune-related AEs

    Time frame: Up to 1 year after completion of treatment

07

Results

Posted Jan 12, 2026

Participant flow

Participant flow — Overall Study
MilestoneNivolumab + Chemoradiation
Started40
Completed40
Not completed0

Outcome measures

PrimaryRate of Completion of All Adjuvant Immunotherapy

The rate of completion of all adjuvant therapy by patients treated at the maximum tolerated dose (MTD) schedule will be determined and compared to a historical control rate of 52%, the rate of completion of a standard adjuvant cisplatin-based platform to determine feasibility of study treatment

Time frame:
Up to 1 year
Reported as:
Number · percentage of participants
Rate of Completion of All Adjuvant Immunotherapy
percentage of participantsNivolumab + Chemoradiation
Rate of Completion of All Adjuvant Immunotherapy100
SecondaryOverall Response Rate (ORR)

The ORR is based on the best overall response (BOR) recorded from the first day of treatment until time of assessment. The percentages of patients with a best overall response rate of complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) will be determined as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.

Time frame:
Up to 1 year after completion of treatment
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsNivolumab + Chemoradiation
Overall Response Rate (ORR)100
SecondaryNumber of Treatment-related Adverse Events (AEs)

Adverse events will be classified using the National Cancer Institute Common Toxicity Criteria (NCI-CTCAE) version 5.0 by the investigator assessment and reported by frequency of Adverse Events (AEs) attributed as definitely, probably, or possibly related to the study interventions.

Time frame:
Up to 1 year after completion of treatment
Reported as:
Number · adverse events
Number of Treatment-related Adverse Events (AEs)
adverse eventsNivolumab + Chemoradiation
Alanine aminotransferase increased1
Alkaline phosphatase increased1
Allergic rhinitis2
Alopecia1
Anemia11
Anorexia18
Arthralgia1
Bloating1
Blurred vision1
Burn1
Cardiac disorders , Other1
Chills4
Cholesterol high1
Constipation14
Cough4
Dehydration7
Dermatitis radiation15
Diarrhea4
Dizziness8
Dry eye1
Dry mouth42
Dry skin3
Dysgeusia42
Dyspepsia1
Dysphagia19
Dysphasia1
Dyspnea1
Ear and labyrinth disorders, Other3
Ear pain2
Epistaxis4
Eye disorders - Other, specify2
Eye pain2
Fatigue30
Fever2
Gastritis1
Gastroesophageal reflux disease1
Gastrointestinal disorders, Other1
General disorders and administration site conditions - Other, specify2
Gingival pain2
Headache5
Hearing impaired10
Hyperhidrosis1
Hyperkalemia2
Hypermagnesemia1
Hypernatremia1
Hypertension1
Hyperthyroidism3
Hypoalbuminemia3
Hypocalcemia4
Hypokalemia8
Hypomagnesemia1
Hyponatremia15
Hypophosphatemia1
Hypotension3
Hypothyroidism7
Infections and infestations - Other, specify2
Insomnia5
Investigations - Other, specify2
Keratitis1
Lethargy1
Lymph node pain1
Lymphedema4
Lymphocyte count decreased38
Mucositis oral43
Muscle weakness lower limb1
Myalgia1
Nasal congestion2
Nausea36
Neck edema2
Neck pain1
Nervous system disorders, Other1
Neutrophil count decreased15
Non-cardiac chest pain1
Oral pain4
Oropharyngeal pain9
Otitis media1
Pain12
Pain in extremity2
Paresthesia3
Peripheral sensory neuropathy5
Platelet count decreased19
Pruritus1
Psychiatric disorders, Other2
Rash acneiform1
Rash maculo-papular1
Respiratory, thoracic and mediastinal disorders, Other2
Sepsis1
Shingles2
Sinusitis4
Skin and subcutaneous tissue disorders - Other, specify25
Skin hyperpigmentation2
Skin infection2
Skin ulceration1
Sore throat10
Thrush10
Tinnitus18
Tremor1
Urticaria2
Voice alteration1
Vomiting7
Weight loss44
White blood cell decreased17
SecondaryMean Loco-regional Control (LRC) Rate

Duration of LRC will be calculated as 1+ the number of days from the first day of treatment to time of documented locoregional clinical or radiographic relapse, progression or death due to any cause. For patients who continue treatment post-progression, the date of clinical or radiographic relapse or progression will be used for analysis. The Kaplan-Meier analysis will be used to calculate the mean LRC rate with full range.

Time frame:
Up to 1 year after completion of treatment
Reported as:
Mean · days
Mean Loco-regional Control (LRC) Rate
daysNivolumab + Chemoradiation
Mean Loco-regional Control (LRC) Rate96 (89 to 99.6)
SecondaryMean Distant Metastasis (DM) Rate

Time to DM will be calculated as 1+ the number of days from the first day of treatment to documented clinical or radiographic progression at a distant metastatic site, or death due to any cause. Pathologic confirmation is not required to document the date of distant progression. For patients who continue treatment post-progression, the date of clinical or radiographic progression will be used for analysis. The Kaplan-Meier analysis will be used to calculate the mean DM rate with full range.

Time frame:
Up to 1 year after completion of treatment
Reported as:
Mean · days

No measurements were reported for this outcome.

SecondaryMean Change in Scores on the Functional Assessment of Cancer Therapy - Nasopharyngeal Cancer (FACT-NP)

The FACT-NP is a self-report instrument that measures multidimensional quality of life (QOL) in patients with Nasopharyngeal cancer-specific scale. The FACT-NP consists of 43 questions that address physical, social, emotional, and functional well-being, with additional specific questions relevant to persons with nasopharyngeal cancers. Each item has a score range of 0 (Not at all) to 4 (Very much). For the 37 general health and head and neck cancer sections, the raw score range is 0-148, with the higher scores indicating better QOL reported by the participant. The 6 remaining questions for the nasopharyngeal cancers also fall on the same range of 0 to 4, with a raw total score range of 0-24, but on this subscale, lower scores indicate a higher QOL.

Time frame:
Up to 1 year after completion of treatment
Reported as:
Mean · scores on a scale
Mean Change in Scores on the Functional Assessment of Cancer Therapy - Nasopharyngeal Cancer (FACT-NP)
scores on a scaleNivolumab + Chemoradiation
Mean Change in Scores on the Functional Assessment of Cancer Therapy - Nasopharyngeal Cancer (FACT-NP)3.7 ± 1.2
SecondaryPercentage of Participants With Acute Toxicities

Acute toxicity rates will be reported and classified according to CTCAE version 5 and include immune-related AEs

Time frame:
Up to 1 year after completion of treatment
Reported as:
Number · percentage of participants
Percentage of Participants With Acute Toxicities
percentage of participantsNivolumab + Chemoradiation
Percentage of Participants With Acute Toxicities100
SecondaryPercentage of Participants With Late Toxicities

Late toxicity rates will be reported and classified according to CTCAE version 5 and include immune-related AEs

Time frame:
Up to 1 year after completion of treatment
Reported as:
Number · percentage of participants
Percentage of Participants With Late Toxicities
percentage of participantsNivolumab + Chemoradiation
Percentage of Participants With Late Toxicities100

Adverse events

Collected over Up to 1 year after completion of treatment, approximately 18 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nivolumab + Chemoradiation0/40 (0%)4/40 (10%)40/40 (100%)
Most frequent serious events
Most frequent serious events
EventNivolumab + Chemoradiation
HypotensionVascular disorders2/40
Abdominal PainGastrointestinal disorders1/40
SyncopeNervous system disorders1/40
Myocardial infarctionCardiac disorders1/40
Infections and infestations - Other, specifyInfections and infestations1/40
Most frequent other events
Showing 10 of 120
Most frequent other events
EventNivolumab + Chemoradiation
DysgeusiaNervous system disorders31/40
Dry mouthGastrointestinal disorders30/40
Mucositis oralGastrointestinal disorders28/40
NauseaGastrointestinal disorders27/40
FatigueGeneral disorders25/40
ConstipationGastrointestinal disorders24/40
Weight lossInvestigations24/40
TinnitusEar and labyrinth disorders19/40
Skin and subcutaneous tissue disorders - Other, specifySkin and subcutaneous tissue disorders18/40
Dermatitis radiationInjury, poisoning and procedural complications16/40

Baseline characteristics

Age, Customized
Age, Customized(Participants)Nivolumab + Chemoradiation
30-39 years old3
40-49 years old11
50-59 years old11
60-69 years old13
70-79 years old2
Sex: Female, Male
Sex: Female, Male(Participants)Nivolumab + Chemoradiation
Female9
Male31
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nivolumab + Chemoradiation
American Indian or Alaska Native1
Asian38
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported1
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nivolumab + Chemoradiation
Hispanic or Latino0
Not Hispanic or Latino40
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Nivolumab + Chemoradiation
United States25
Singapore15
08

Study locations

2 sites
  • University of California, San Francisco
    San Francisco, California 94143, United States
  • National University Hospital Singapore
    Singapore, 119074, Singapore
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Oct 2024, 80 months.

Results were first posted in Jan 2026, 1 year 2 months after primary completion.

Of 128 non-industry phase 2 interventional studies under Nasopharyngeal Carcinoma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 74. This study's 80 months is above that.

Counting every sponsor, half of 143 studies reached it within 43 months; a quarter within 28 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2017
First posted
Aug 30, 2017
StartActual
Feb 14, 2018
Primary completionActual
Oct 31, 2024
CompletionActual
Oct 31, 2024
Results first posted
Jan 12, 2026
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03267498
Lead sponsor
Sue Yom
Responsible party
Sue Yom (Principal Investigator, University of California, San Francisco) — Sponsor-investigator
First posted
Aug 30, 2017
Start date
Feb 14, 2018
Primary completion
Oct 31, 2024
Completion
Oct 31, 2024
Results posted
Jan 12, 2026
Last update
Jan 12, 2026

Study contacts

Sue S Yom, MD, PhD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion